22808-73-7Relevant articles and documents
Novel benzenesulfonamides aryl and arylsulfone conjugates adopting tail/dual tail approaches: Synthesis, carbonic anhydrase inhibitory activity and molecular modeling studies
Eldeeb, Assem H.,Abo-Ashour, Mahmoud F.,Angeli, Andrea,Bonardi, Alessandro,Lasheen, Deena S.,Elrazaz, Eman Z.,Nocentini, Alessio,Gratteri, Paola,Abdel-Aziz, Hatem A.,Supuran, Claudiu T.
supporting information, (2021/05/10)
New series of benzenesulfonamide and benzoic acid derivatives were designed and synthesized using tail/dual tail approach to improve potency and selectivity as carbonic anhydrase inhibitors. The synthesized compounds evaluated as CAIs against isoforms hCA I, II, IV and IX with acetazolamide (AAZ) as standard inhibitor. The benzenesulfonamide derivatives 7a-d, 8a-h, 12a-c, 13a and 15a-c showed moderate to potent inhibitory activity with selectivity toward isoform hCA II, especially, compound 13a with (Ki = 7.6 nM), while the benzoic acid analogues 12d-f, 13b and 15d-f didn't show any activity except compounds 12d,f and 15e that showed weak activity. Additionally, molecular docking was performed for compounds 7a, 8a, 8e, 12a, 13a and 15a on isoform hCA I, II to illustrate the possible interaction with the active site to justify the inhibitory activity.
Oxadiazole substituted benzenesulfonamide compound and preparation method thereof and application as carbonic anhydrase inhibitor
-
Paragraph 0059-0063, (2020/04/02)
The invention discloses an oxadiazole substituted benzenesulfonamide compound as shown in a formula I or pharmaceutically acceptable salt thereof, a preparation method of the oxadiazole substituted benzenesulfonamide compound and an application of the oxadiazole substituted benzenesulfonamide compound as a carbonic anhydrase inhibitor. The compound is simple in preparation process, mild in reaction conditions in key steps, higher in yield, lower in energy consumption and more environment-friendly, and the compound shows a good development potential as a carbonic anhydrase inhibitor.
4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors
Yang, Lingling,Chen, Yang,He, Junlin,Njoya, Emmanuel Mfotie,Chen, Jianjun,Liu, Siyan,Xie, Congqiang,Huang, Wenze,Wang, Fei,Wang, Zhouyu,Li, Yuzhi,Qian, Shan
, p. 1087 - 1098 (2019/02/19)
Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) are constitutively overexpressed in many types of cancer cells and exert important immunosuppressive functions. In this article, a series of 4,6-substituted-1H-indazole derivatives were synthesized and evaluated the inhibitory activities against IDO1 and TDO, as well as their structure-activity relationships (SARs). Among these, compound 35 displayed the most IDO1 inhibitory potency with an IC50 value of 0.74 μM in an enzymatic assay and 1.37 μM in HeLa cells. Quantitative analysis of the Western blot results indicated that 35 significantly decreased the INFγ-induced IDO1 expression in a concentration-dependent manner. In addition, 35 showed promising TDO inhibition with an IC50 value of 2.93 μM in the enzymatic assay and 7.54 μM in A172 cells. Moreover, compound 35 exhibited in vivo antitumor activity in the CT26 xenograft model. These findings suggest that 1H-indazole derivative 35 is a potent IDO1/TDO dual inhibitor, and has the potential to be developed for IDO1/TDO-related cancer treatment.